From the lab to COVID front lines AbbVie will provide $30 million over three years and additional in-kind support leveraging AbbVie’s scientists, expertise and facilities to advance collaborative research and early-stage development efforts across five program areas that address a variety of therapeutic modalities:Immunity and immunopathology — Study of the fundamental processes that impact the body’s critical immune responses to viruses and identification of opportunities for therapeutic intervention.Led by Uli Von Andrian, Mallinckrodt Professor of Immunopathology in the Blavatnik Institute at HMS and program leader of basic immunology at the Ragon Institute of MGH, MIT, and Harvard; and by Jochen Salfeld, vice president, immunology and virology discovery at AbbVie.Host targeting for antiviral therapies — Development of approaches that modulate host proteins in an effort to disrupt the life cycle of emergent viral pathogens.Led by Pamela Silver, Elliot T. and Onie H. Adams Professor of Biochemistry and Systems Biology in the Blavatnik Institute at HMS; and by Steve Elmore, vice president, drug discovery science and technology at AbbVie.Antibody therapeutics — Rapid development of therapeutic antibodies or biologics against emergent pathogens, including SARS-CoV-2, to a preclinical or early-clinical stage.Led by Jonathan Abraham, assistant professor of microbiology in the Blavatnik Institute at HMS; and by Jochen Salfeld, vice president, immunology and virology discovery at AbbVie.Small molecules — Discovery and early-stage development of small-molecule drugs that would act to prevent replication of known coronaviruses and emergent pathogens.Led by Mark Namchuk, executive director of therapeutics translation at HMS and senior lecturer of biological chemistry and molecular pharmacology in the Blavatnik Institute at HMS; and by Steve Elmore, vice president, drug discovery science and technology at AbbVie.Translational development — Preclinical validation, pharmacological testing, and optimization of leading approaches, in collaboration with Harvard-affiliated hospitals, with program leads to be determined. $16.5 million awarded to projects to fight COVID Chan School’s Michael Mina urges federal regulatory approval, widespread use Technology developed at Harvard provides early boost to Mass. COVID testing Harvard University and AbbVie today announced a $30 million collaborative research alliance, launching a multi-pronged effort at Harvard Medical School (HMS) to study and develop novel therapies against emergent viral infections, with a focus on those caused by coronaviruses and by viruses that lead to hemorrhagic fever.This collaboration aims to rapidly integrate fundamental biology into the preclinical and clinical development of new therapies for viral diseases that address a variety of therapeutic modalities. HMS has led several large-scale, coordinated research efforts launched at the beginning of the COVID-19 pandemic.“A key element of having a strong R&D organization is collaboration with top academic institutions, like Harvard Medical School, to develop therapies for patients who need them most,” said Michael Severino, vice chairman and president of AbbVie. “There is much to learn about viral diseases and the best way to treat them. By harnessing the power of collaboration, we can develop new therapeutics sooner to ensure the world is better prepared for future potential outbreaks.”“The cataclysmic nature of the COVID-19 pandemic reminds us how vital it is to be prepared for the next public health crisis and how critical collaboration is on every level — across disciplines, across institutions, and across national boundaries,” said George Q. Daley, dean of Harvard Medical School. “Harvard Medical School, as the nucleus of an ecosystem of fundamental discovery and therapeutic translation, is uniquely positioned to propel this transformative research alongside allies like AbbVie.” Related MassCPR collaboration funds plans with promise to help in a year Cheap, frequent COVID tests could be ‘akin to vaccine,’ professor says
McDermott has been awarded a sizeable contract by LLOG for deepwater subsea pipeline tiebacks and structures from the Stonefly development to the Ram Powell platform, located approximately 140 miles southeast of New Orleans, Louisiana.McDermott’s spoolbase in Gulfport, Mississippi. Source: McDermottLLOG sanctioned the development of the Stonefly discovery in the Gulf of Mexico in September 2018 with plans to start first production in December 2019.McDermott said on Monday that its scope of work includes project management, installation engineering, subsea structure and spoolbase stalk fabrication, and subsea installation of the subsea infrastructure to support a two well subsea tieback from the Stonefly development site to the Ram Powell platform via a 60,000 foot 6-inch pipeline at water depths ranging from 3,300 to 4,100 feet.McDermott will also design, fabricate, and install a steel catenary riser, a pipeline end manifold, and two in-line sleds.“This award demonstrates McDermott’s commitment to helping LLOG safely and competitively deliver the Stonefly development,” said Richard Heo, McDermott’s Senior Vice President for North, Central and South America.The Stonefly development includes the Viosca Knoll 999 area where McDermott is scheduled to use its 50-acre spoolbase in Gulfport, Mississippi, for fabrication and reeled solutions. McDermott is scheduled to install the subsea tiebacks and structures using its North Ocean 105 vessel in the third quarter of 2019. Structure design and installation engineering began in January 2019 in McDermott’s Houston office.McDermott defines a sizeable contract as between $1 million and $50 million. The lump sum contract award will be reflected in McDermott’s first quarter 2019 backlog.The Ram Powell tension leg platform is located in 3,200 feet of water in Viosca Knoll Area, Block 956, and is capable of processing 60,000 barrels of oil per day and 200 million cubic feet of gas per day.